Literature DB >> 24891301

Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa mice.

Jacen S Maier-Moore1, Christopher G Horton, Shirley A Mathews, Anthony W Confer, Christina Lawrence, Zijian Pan, K Mark Coggeshall, A Darise Farris.   

Abstract

OBJECTIVE: To assess disease features in Sle1.Yaa mice with genetic interleukin-6 (IL-6) deficiency.
METHODS: Sera and tissues were collected from C57BL/6 (B6), Sle1.Yaa, and Sle1.Yaa.IL-6(-/-) mice and analyzed for various features of disease. Using serum samples, autoantibody specificities were determined by enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence, cytokine production was analyzed by Luminex and ELISA, and levels of blood urea nitrogen were determined by ELISA. Renal, lung, and salivary gland tissue sections were evaluated for pathologic changes. Lymphocyte phenotypes, including CD4+ T cell cytokine production, and those of follicular and extrafollicular T helper subsets, germinal center B cells, and plasma cells, were determined using flow cytometry.
RESULTS: IL-6 deficiency not only ameliorated autoantibody production and renal disease in this model, but also effectively reduced inflammation of lungs and salivary glands. Furthermore, IL-6 deficiency abrogated differentiation of Th1 and extrafollicular T helper cells, germinal center B cells, and plasma cells in the spleen and eliminated renal T cells with IL-17, interferon-γ, and IL-21 production potential.
CONCLUSION: Our findings highlight IL-6-mediated T cell aberrations in Yaa-driven autoimmunity and support the concept of therapeutic IL-6/IL-6 receptor blockade in systemic lupus erythematosus and Sjögren's syndrome by impairing the production of autoantibodies and lymphocytic infiltration of the kidneys, lungs, and salivary glands.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24891301      PMCID: PMC4146640          DOI: 10.1002/art.38716

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  47 in total

1.  Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Authors:  M A Munger; B Johnson; I J Amber; K S Callahan; E M Gilbert
Journal:  Am J Cardiol       Date:  1996-04-01       Impact factor: 2.778

2.  Cellular localization of inflammatory cytokines in human glomerulonephritis.

Authors:  T Takemura; K Yoshioka; K Murakami; N Akano; M Okada; N Aya; S Maki
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 3.  Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis.

Authors:  Y Horii; M Iwano; E Hirata; M Shiiki; Y Fujii; K Dohi; H Ishikawa
Journal:  Kidney Int Suppl       Date:  1993-01       Impact factor: 10.545

4.  IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice.

Authors:  M Mihara; N Takagi; Y Takeda; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

5.  Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice.

Authors:  E Fattori; C Della Rocca; P Costa; M Giorgio; B Dente; L Pozzi; G Ciliberto
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

6.  Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome.

Authors:  C P Robinson; J Brayer; S Yamachika; T R Esch; A B Peck; C A Stewart; E Peen; R Jonsson; M G Humphreys-Beher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

7.  Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow.

Authors:  H Kitamura; H Kawata; F Takahashi; Y Higuchi; T Furuichi; H Ohkawa
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

8.  IgG1 plasmacytosis in interleukin 6 transgenic mice.

Authors:  S Suematsu; T Matsuda; K Aozasa; S Akira; N Nakano; S Ohno; J Miyazaki; K Yamamura; T Hirano; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome.

Authors:  Keiko Yoshimoto; Maiko Tanaka; Masako Kojima; Yumiko Setoyama; Hideto Kameda; Katsuya Suzuki; Kensei Tsuzaka; Yoko Ogawa; Kazuo Tsubota; Tohru Abe; Tsutomu Takeuchi
Journal:  Arthritis Res Ther       Date:  2011-10-21       Impact factor: 5.156

10.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  10 in total

1.  Defective selection of thymic regulatory T cells accompanies autoimmunity and pulmonary infiltrates in Tcra-deficient mice double transgenic for human La/Sjögren's syndrome-B and human La-specific TCR.

Authors:  Jane C Yaciuk; Yujun Pan; Karen Schwarz; Zi-Jian Pan; Jacen S Maier-Moore; Stanley D Kosanke; Christina Lawrence; A Darise Farris
Journal:  J Immunol       Date:  2015-01-12       Impact factor: 5.422

2.  Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon Loop.

Authors:  Jasmine N Stannard; Tamra J Reed; Emily Myers; Lori Lowe; Mrinal K Sarkar; Xianying Xing; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  J Invest Dermatol       Date:  2016-09-16       Impact factor: 8.551

Review 3.  Malignancies in systemic lupus erythematosus: a 2015 update.

Authors:  Gillian C Goobie; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Curr Opin Rheumatol       Date:  2015-09       Impact factor: 5.006

4.  Lupus Susceptibility Loci Predispose Mice to Clonal Lymphocytic Responses and Myeloid Expansion.

Authors:  Elliot H Akama-Garren; Michael C Carroll
Journal:  J Immunol       Date:  2022-04-27       Impact factor: 5.426

5.  Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous.

Authors:  Vanessa Ocampo; Derek Haaland; K Legault; Shika Mittoo; Emily Aitken
Journal:  BMJ Case Rep       Date:  2016-08-08

6.  Induction therapy downregulates the expression of Th17/Tfh cytokines in patients with active lupus nephritis.

Authors:  Na Wang; Congcong Gao; Siwan Cui; Yilu Qin; Chunyi Zhang; Peiwen Yi; Xueqi Di; Shengyun Liu; Tianfang Li; Guanmin Gao; Zhaohui Zheng
Journal:  Am J Clin Exp Immunol       Date:  2018-08-20

7.  Dexmedetomidine Modulates Histamine-induced Ca(2+) Signaling and Pro-inflammatory Cytokine Expression.

Authors:  Dongki Yang; Jeong Hee Hong
Journal:  Korean J Physiol Pharmacol       Date:  2015-08-20       Impact factor: 2.016

8.  BANK1 Regulates IgG Production in a Lupus Model by Controlling TLR7-Dependent STAT1 Activation.

Authors:  Ying-Yu Wu; Ramesh Kumar; Ryuji Iida; Harini Bagavant; Marta E Alarcón-Riquelme
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

Review 9.  Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus.

Authors:  Timothy A Gottschalk; Evelyn Tsantikos; Margaret L Hibbs
Journal:  Front Immunol       Date:  2015-10-28       Impact factor: 7.561

10.  Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.

Authors:  Matthew Baker; Yashaar Chaichian; Mark Genovese; Vimal Derebail; Panduranga Rao; Winn Chatham; Michael Bubb; Sam Lim; Hooman Hajian; Oksana Gurtovaya; Uptal Patel; James Tumlin
Journal:  RMD Open       Date:  2020-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.